search icon
bhvn-img

Biohaven Pharmaceutical Holding Co Ltd, Common Stock

BHVN

NYQ

$37.48

+$0.76

(2.07%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$3.56B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.09M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
4.12
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$26.8 L
$62.21 H
$37.48

About Biohaven Pharmaceutical Holding Co Ltd, Common Stock

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. Biohaven Ltd. was formerly a subsidiary of Biohaven Pharmaceutical Holding Company Ltd. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameBHVNSectorS&P500
1-Week Return-3.58%1.76%-2.5%
1-Month Return-2.57%0.33%-3.91%
3-Month Return-28.97%-8.58%-0.59%
6-Month Return-2.52%-4.26%3.45%
1-Year Return-15.96%1.27%22.31%
3-Year Return413.42%5.33%25%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue--462.51M--[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue-72.00K91.66M1.39M3.37M[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":0.08,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":1.51,"profit":true},{"date":"2023-12-31","value":3.68,"profit":true}]
Gross Profit-(72.00K)370.85M(1.39M)(3.37M)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-0.02,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-0.37,"profit":false},{"date":"2023-12-31","value":-0.91,"profit":false}]
Gross Margin--80.18%--[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Operating Expenses479.12M114.51M218.90M567.93M436.05M[{"date":"2019-12-31","value":84.36,"profit":true},{"date":"2020-12-31","value":20.16,"profit":true},{"date":"2021-12-31","value":38.54,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":76.78,"profit":true}]
Operating Income(479.12M)(114.51M)(218.90M)(567.93M)(436.05M)[{"date":"2019-12-31","value":-47912200000,"profit":false},{"date":"2020-12-31","value":-11450600000,"profit":false},{"date":"2021-12-31","value":-21890000000,"profit":false},{"date":"2022-12-31","value":-56793200000,"profit":false},{"date":"2023-12-31","value":-43605100000,"profit":false}]
Total Non-Operating Income/Expense-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Pre-Tax Income(528.39M)(118.67M)(212.43M)(569.84M)(409.55M)[{"date":"2019-12-31","value":-52838600000,"profit":false},{"date":"2020-12-31","value":-11866800000,"profit":false},{"date":"2021-12-31","value":-21243000000,"profit":false},{"date":"2022-12-31","value":-56984100000,"profit":false},{"date":"2023-12-31","value":-40955100000,"profit":false}]
Income Taxes419.00K(134.30K)1.37M438.00K(1.38M)[{"date":"2019-12-31","value":30.67,"profit":true},{"date":"2020-12-31","value":-9.83,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":32.06,"profit":true},{"date":"2023-12-31","value":-101.24,"profit":false}]
Income After Taxes-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Income From Continuous Operations-(118.67M)(848.40M)(570.28M)(408.17M)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-11866800000,"profit":false},{"date":"2021-12-31","value":-84839600000,"profit":false},{"date":"2022-12-31","value":-57027900000,"profit":false},{"date":"2023-12-31","value":-40816800000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(528.80M)(118.67M)(213.80M)(570.28M)(408.17M)[{"date":"2019-12-31","value":-52880500000,"profit":false},{"date":"2020-12-31","value":-11866800000,"profit":false},{"date":"2021-12-31","value":-21379600000,"profit":false},{"date":"2022-12-31","value":-57027900000,"profit":false},{"date":"2023-12-31","value":-40816800000,"profit":false}]
EPS (Diluted)(10.97)(13.04)(13.08)(14.25)(5.66)[{"date":"2019-12-31","value":-1097,"profit":false},{"date":"2020-12-31","value":-1304,"profit":false},{"date":"2021-12-31","value":-1308,"profit":false},{"date":"2022-12-31","value":-1425,"profit":false},{"date":"2023-12-31","value":-566,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

BHVN
Cash Ratio 2.49
Current Ratio 2.89
Quick Ratio 2.93

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

BHVN
ROA (LTM) -118.79%
ROE (LTM) -265.45%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

BHVN
Debt Ratio Lower is generally better. Negative is bad. 0.38
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.62

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

BHVN
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 11.75
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Biohaven Pharmaceutical Holding Co Ltd share price today?

Biohaven Pharmaceutical Holding Co Ltd (BHVN) share price today is $37.48

Can Indians buy Biohaven Pharmaceutical Holding Co Ltd shares?

Yes, Indians can buy shares of Biohaven Pharmaceutical Holding Co Ltd (BHVN) on Vested. To buy Biohaven Pharmaceutical Holding Co Ltd from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BHVN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Biohaven Pharmaceutical Holding Co Ltd be purchased?

Yes, you can purchase fractional shares of Biohaven Pharmaceutical Holding Co Ltd (BHVN) via the Vested app. You can start investing in Biohaven Pharmaceutical Holding Co Ltd (BHVN) with a minimum investment of $1.

How to invest in Biohaven Pharmaceutical Holding Co Ltd shares from India?

You can invest in shares of Biohaven Pharmaceutical Holding Co Ltd (BHVN) via Vested in three simple steps:

  • Click on Sign Up or Invest in BHVN stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Biohaven Pharmaceutical Holding Co Ltd shares
What is Biohaven Pharmaceutical Holding Co Ltd 52-week high and low stock price?

The 52-week high price of Biohaven Pharmaceutical Holding Co Ltd (BHVN) is $62.21. The 52-week low price of Biohaven Pharmaceutical Holding Co Ltd (BHVN) is $26.8.

What is Biohaven Pharmaceutical Holding Co Ltd price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Biohaven Pharmaceutical Holding Co Ltd (BHVN) is

What is Biohaven Pharmaceutical Holding Co Ltd price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Biohaven Pharmaceutical Holding Co Ltd (BHVN) is 11.75

What is Biohaven Pharmaceutical Holding Co Ltd dividend yield?

The dividend yield of Biohaven Pharmaceutical Holding Co Ltd (BHVN) is 0.00%

What is the Market Cap of Biohaven Pharmaceutical Holding Co Ltd?

The market capitalization of Biohaven Pharmaceutical Holding Co Ltd (BHVN) is $3.56B

What is Biohaven Pharmaceutical Holding Co Ltd’s stock symbol?

The stock symbol (or ticker) of Biohaven Pharmaceutical Holding Co Ltd is BHVN

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top